Key facts
as of Sep 2026- It has raised $130.0M; the latest was Later Stage VC in Mar 2026.
- Notable investors include Hefei Industry Investment Group, Hefei Hi-Tech VC, V-Capital, Shanghai Alliance Investment, Suzhou Yuanfeng Capital Management — 10 tracked in total.
- 11 institutional filers report fund marks on Coherent Biopharma across 91 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Coherent Biopharma
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Coherent Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
11 filers · latest Jun 202611 SEC-registered funds reported 91 fair-value marks on Coherent Biopharma between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Coherent Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Coherent Biopharma
Developer of biopharmaceutical drugs designed to advance targeted therapies for cancer and other serious diseases. The company offers bi-targeting drug conjugate technology, proprietary ligand discovery platforms and targeted payload delivery mechanisms, enabling healthcare researchers and oncology patients to access precision therapeutics with improved cellular targeting and therapeutic efficacy
- Sector
- Healthcare
- HQ
- Suzhou, China
- Employees
- 100
- Website
- coherentbio.com/
- Ownership
- Privately Held (backing)